FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2106974977> ?p ?o ?g. }

• W2106974977 endingPage "3954" @default.
• W2106974977 startingPage "3945" @default.
• W2106974977 abstract "Abstract Purpose: HSP90 chaperones have key client proteins that are involved in all hallmarks of breast cancer growth and progression. The primary aim of this clinical trial was to evaluate the feasibility of using 89Zr-trastuzumab PET (for HER2-positive breast cancer) or 89Zr-bevacizumab PET [for estrogen receptor (ER)–positive breast cancer] to determine in vivo degradation of client proteins caused by the novel HSP90 inhibitor NVP-AUY922. Experimental Design: Of note, 70 mg/m2 NVP-AUY922 was administered intravenously in a weekly schedule to patients with advanced HER2 or ER-positive breast cancer. Biomarker analysis consisted of serial PET imaging with 2[18F]fluoro-2-deoxy-D-glucose (FDG), 89Zr-trastuzumab, or 89Zr-bevacizumab. Response evaluation was performed according to RECIST1.0. FDG, 89Zr-trastuzumab, and 89Zr-bevacizumab distributions were scored visually and quantitatively by calculating the maximum standardized uptake values (SUVmax). In blood samples, serial HSP70 levels, extracellular form of HER2 (HER2-ECD), and pharmacokinetic and pharmacodynamic parameters were measured. Results: Sixteen patients (ten HER2-positive and six ER-positive tumors) were included. One partial response was observed; seven patients showed stable disease. SUVmax change in individual tumor lesions on baseline versus 3 weeks 89Zr-trastuzumab PET was heterogeneous and related to size change on CT after 8 weeks treatment (r2 = 0.69; P = 0.006). Tumor response on 89Zr-bevacizumab PET and FDG-PET was not correlated with CT response. Conclusions: NVP-AUY922 showed proof-of-concept clinical response in HER2-amplified metastatic breast cancer. Early change on 89Zr-trastuzumab PET was positively associated with change in size of individual lesions assessed by CT. Clin Cancer Res; 20(15); 3945–54. ©2014 AACR." @default.
• W2106974977 created "2016-06-24" @default.
• W2106974977 creator A5001423670 @default.
• W2106974977 creator A5004861959 @default.
• W2106974977 creator A5011165801 @default.
• W2106974977 creator A5016475369 @default.
• W2106974977 creator A5019036811 @default.
• W2106974977 creator A5021010274 @default.
• W2106974977 creator A5032401979 @default.
• W2106974977 creator A5033624935 @default.
• W2106974977 creator A5045446273 @default.
• W2106974977 creator A5058800375 @default.
• W2106974977 creator A5061495577 @default.
• W2106974977 creator A5072881153 @default.
• W2106974977 creator A5091068795 @default.
• W2106974977 date "2014-07-31" @default.
• W2106974977 modified "2023-10-10" @default.
• W2106974977 title "89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients" @default.
• W2106974977 cites W1596105818 @default.
• W2106974977 cites W1967438857 @default.
• W2106974977 cites W1970460458 @default.
• W2106974977 cites W1984999768 @default.
• W2106974977 cites W1988219667 @default.
• W2106974977 cites W1993093755 @default.
• W2106974977 cites W1999715990 @default.
• W2106974977 cites W2000929246 @default.
• W2106974977 cites W2012505736 @default.
• W2106974977 cites W2028978816 @default.
• W2106974977 cites W2060730827 @default.
• W2106974977 cites W2061792764 @default.
• W2106974977 cites W2080053266 @default.
• W2106974977 cites W2097277023 @default.
• W2106974977 cites W2100214216 @default.
• W2106974977 cites W2103563357 @default.
• W2106974977 cites W2108549165 @default.
• W2106974977 cites W2114032749 @default.
• W2106974977 cites W2117114191 @default.
• W2106974977 cites W2117692326 @default.
• W2106974977 cites W2120798040 @default.
• W2106974977 cites W2122767481 @default.
• W2106974977 cites W2126429511 @default.
• W2106974977 cites W2130870133 @default.
• W2106974977 cites W2131384028 @default.
• W2106974977 cites W2137374006 @default.
• W2106974977 cites W2139248078 @default.
• W2106974977 cites W2150575159 @default.
• W2106974977 cites W2153982924 @default.
• W2106974977 cites W2158437743 @default.
• W2106974977 cites W2162740426 @default.
• W2106974977 cites W2163069245 @default.
• W2106974977 cites W2165819904 @default.
• W2106974977 cites W2166999544 @default.
• W2106974977 cites W2171708713 @default.
• W2106974977 cites W2519006788 @default.
• W2106974977 cites W3011380444 @default.
• W2106974977 doi "https://doi.org/10.1158/1078-0432.ccr-14-0491" @default.
• W2106974977 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25085789" @default.
• W2106974977 hasPublicationYear "2014" @default.
• W2106974977 type Work @default.
• W2106974977 sameAs 2106974977 @default.
• W2106974977 citedByCount "101" @default.
• W2106974977 countsByYear W21069749772014 @default.
• W2106974977 countsByYear W21069749772015 @default.
• W2106974977 countsByYear W21069749772016 @default.
• W2106974977 countsByYear W21069749772017 @default.
• W2106974977 countsByYear W21069749772018 @default.
• W2106974977 countsByYear W21069749772019 @default.
• W2106974977 countsByYear W21069749772020 @default.
• W2106974977 countsByYear W21069749772021 @default.
• W2106974977 countsByYear W21069749772022 @default.
• W2106974977 countsByYear W21069749772023 @default.
• W2106974977 crossrefType "journal-article" @default.
• W2106974977 hasAuthorship W2106974977A5001423670 @default.
• W2106974977 hasAuthorship W2106974977A5004861959 @default.
• W2106974977 hasAuthorship W2106974977A5011165801 @default.
• W2106974977 hasAuthorship W2106974977A5016475369 @default.
• W2106974977 hasAuthorship W2106974977A5019036811 @default.
• W2106974977 hasAuthorship W2106974977A5021010274 @default.
• W2106974977 hasAuthorship W2106974977A5032401979 @default.
• W2106974977 hasAuthorship W2106974977A5033624935 @default.
• W2106974977 hasAuthorship W2106974977A5045446273 @default.
• W2106974977 hasAuthorship W2106974977A5058800375 @default.
• W2106974977 hasAuthorship W2106974977A5061495577 @default.
• W2106974977 hasAuthorship W2106974977A5072881153 @default.
• W2106974977 hasAuthorship W2106974977A5091068795 @default.
• W2106974977 hasBestOaLocation W21069749772 @default.
• W2106974977 hasConcept C111113717 @default.
• W2106974977 hasConcept C112705442 @default.
• W2106974977 hasConcept C121608353 @default.
• W2106974977 hasConcept C126322002 @default.
• W2106974977 hasConcept C143998085 @default.
• W2106974977 hasConcept C185592680 @default.
• W2106974977 hasConcept C2775930923 @default.
• W2106974977 hasConcept C2776694085 @default.
• W2106974977 hasConcept C2777802072 @default.
• W2106974977 hasConcept C2779786085 @default.
• W2106974977 hasConcept C2781197716 @default.
• W2106974977 hasConcept C530470458 @default.

• next